Calls for papers
-
SMI developer Resyca has announced the appointment of former Proveris Scientific Sales Director for Europe and India Deborah Jones as its new CEO, following the resignation of Remko Beimers. Jones joined Proveris in 2016 after… Read more . . .
-
The 2026 edition of the Respiratory Drug Delivery conference, organized by RDD Online, will take place May 10-14 at the Westin Kierland Resort in Scottsdale, AZ, USA. RDD Online’s Richard Dalby says that organizers expect… Read more . . .
-
Belgian biotech Cannovex and Dutch DPI developer PureIMS announced that Cannovex has acquired exclusive rights to develop pharmaceutical cannabinoid products delivered via PureIMS’s Cyclops high-dose dry powder inhaler. The companies say that they have entered… Read more . . .
-
According to Dompé, researchers at the Agostino Gemelli IRCCS University Hospital in Rome, Italy have initiated a Phase 2 trial of Dompé’s intranasal formulation of cenegermin-bkbj, a recombinant human nerve growth factor, in patients with… Read more . . .
-
According to Agomab, the US Patent and Trademark Office (USPTO) has granted a composition of matter patent (US Patent No. 12,577,230) covering the company’s AGMB-447 inhaled ALK5 (TGFβR1) inhibitor through 2041. Agomab is developing AGMB-447… Read more . . .
-
ARS Pharmaceuticals announced that the FDA has approved an sNDA to remove the age requirement for the 1 mg dose of neffy epinephrine nasal spray for the treatment of anaphylaxis. A 2 mg dose of… Read more . . .
-
According to United Therapeutics, the Phase 3 TETON-1 trial of nebulized Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis met its primary endpoint, demonstrating a 130.1 mL change in absolute FVC from baseline to… Read more . . .
-
According to Tonix Pharmaceuticals, researchers at Erasmus University Medical Center have initiated a Phase 1 study of Tonix’s TNX-1900 intranasal potentiated oxytocin in healthy female volunteers as a proof of concept for the potential use… Read more . . .
-
In April 2025, Avalyn Pharma announced plans to advance its AP02 nintedanib inhalation solution into a Phase 2 trial in patients with idiopathic pulmonary fibrosis. Avalyn has now announced the initiation of the Phase 2… Read more . . .
-
Everest Medicines announced that it has acquired Chinese development, manufacturing, and commercialization rights to Cardamyst etripamil nasal spray from Corxel Pharmaceuticals Hong Kong (formerly Ji Xing Pharmaceuticals). Ji Xing acquired the Chinese rights to etripamil… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA